Cardiovascular DiseasePhase 3CIRTNCT01594333
Cardiovascular Inflammation Reduction Trial
A Phase 3 study testing Methotrexate in people with Cardiovascular Disease, run by Brigham and Women's Hospital at 470 sites in 3 countries.
Trial summary
The Cardiovascular Inflammation Reduction Trial (CIRT) is a randomized clinical trial investigating whether taking low-dose methotrexate reduces heart attacks, strokes, or death in people with type 2 diabetes or metabolic syndrome that have had a heart attack or multiple coronary blockages. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Cardiovascular Disease
- What is being tested?
- Methotrexate
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 4,786 participants
- Where
- 470 sitesin 3 countries
- Study dates
- Apr 2013to 30 Oct 2019
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age ≥ 18 years at screening
- Documented past history of myocardial infarction OR past evidence of multivessel coronary artery disease by angiography.
- To qualify on the basis of past history of myocardial infarction, the event must be documented either by hospital records or by evidence on current ECG of Q waves in two contiguous leads and/or an imaging test demonstrating wall motion abnormality or scar. The patient must also have completed any planned coronary revascularization procedures associated with the qualifying event, and be clinically stable for at least 60 days prior to screening.
- To qualify on the basis of multivessel coronary disease, there must be past angiographic evidence of atherosclerosis in at least 2 major epicardial vessels defined either as the presence of a stent, a coronary bypass graft, or an angiographic lesion of 60% or greater. Left main coronary artery disease that has been revascularized with a stent or bypass graft will qualify as multivessel disease, as will the presence of a 50% or greater isolated left main stenosis. The patient must also have completed any planned coronary revascularization procedures associated with the qualifying event, and be clinically stable for at least 60 days prior to screening.
- History of type 2 diabetes or metabolic syndrome at time of study enrollment
- Willingness to participate as evidenced by signing the study informed consent
Who cannot join
- Prior history of chronic infectious disease, tuberculosis, or severe fungal disease; chronic hepatitis B or C infection; renal insufficiency; interstitial pneumonitis, bronchiectasis, or pulmonary fibrosis; known chronic pericardial effusion, pleural effusion, or ascites; chronic liver disease; myeloproliferative disorders in the past 5 years; non-basal cell malignancy or treated lymphoproliferative disease within the past 5 years; known HIV positive; life expectancy of < 3 years;
- Chronic inflammatory condition such as lupus or rheumatoid arthritis, ulcerative colitis or Crohn's disease
- White blood cell count < 3,500/ul, hematocrit < 32 percent, or platelet count < 75,000/ul
- Liver transaminase levels (AST or ALT) >upper limit of normal (ULN) or albumin < the lower limit of normal (LLN);
- Creatinine clearance < 40 ml/min as estimated with the Cockcroft-Gault equation;
- History of alcohol abuse or unwillingness to limit alcohol consumption to less than 4 drinks per week
Show all 13Show fewer
- Women of child bearing potential, even if they are currently using contraception, and women intending to breastfeed.
- Men who plan to father children during the study period or who are unwilling to use effective forms of contraception.
- Requirement for use of drugs that alter folate metabolism (trimethoprim/sulfamethoxazol) or reduce tubular excretion (probenecid) or known allergies to antibiotics making avoidance of trimethoprim impossible;
- Current indication for methotrexate therapy;
- Chronic use of oral steroid therapy or other immunosuppressive or biologic response modifiers. Eligible study participants will be encouraged to have up to date pneumococcal and influenza vaccinations as recommended based on their age and underlying medical conditions.
- Chest X-ray evidence in the past 12 months of interstitial pneumonitis, bronchiectasis, or pulmonary fibrosis. For participants who do not have a chest X-ray in the prior 12 months, a chest X-ray will be obtained at baseline as part of the study protocol.
- New York Heart Association Class IV congestive heart failure.
Trial locations and contacts
470 sites in 3 countries.
366 sites in 3 countries
United States300 sites
Center for Clinical Res. Abington Health
Abington, Pennsylvania, 19001
Akron General Medical Center
Akron, Ohio, 44307
Albany Medical College
Albany, New York, 12208
Albany Stratton VA Medical Center
Albany, New York, 12208
Presbyterian Heart Group
Albuquerque, New Mexico, 87106
Endeavor Medical Research
Alpena, Michigan, 49707
Oracle Clinical Research, Inc.
Anaheim, California, 92801
Northwest Heart Clinical Research
Arlington Heights, Illinois, 60005
Clinical Study Center of Asheville
Asheville, North Carolina, 28801
Athens Regional Medical Center
Athens, Georgia, 30606
Ohio University Heritage College of Osteopathic Medicine
Athens, Ohio, 45701
Atlanta Veterans Affairs Medical Center
Atlanta, Georgia, 30033
Laureate Medical Group at Northside
Atlanta, Georgia, 30308
Synergy Therapeutic Partners
Atlanta, Georgia, 30308
Northside Hospital
Atlanta, Georgia, 30342
Maine Research Associates
Auburn, Maine, 04210
Avant Research Associates LLC
Austin, Texas, 78704
Texas Heart and Vascular Research, LLC
Austin, Texas, 78745
Pianko - Aventura Research Center, LLC
Aventura, Florida, 33180
Sinai Center for Thrombosis Research
Baltimore, Maryland, 21215
Paul A. Shapero, M.D.
Bangor, Maine, 04401
Southeast TX Clinical Research Center
Beaumont, Texas, 77702
St. Luke's University Hospital
Bethlehem, Pennsylvania, 18018
Southern Maine Health Care
Biddeford, Maine, 04005
Cornerstone Family Medicine
Big Spring, Texas, 79720
University of Alabama at Birmingham
Birmingham, Alabama, 35294
North Ridge Heart Associates
Boca Raton, Florida, 33434
St. Luke's Idaho Cardiology Associates
Boise, Idaho, 83712
Brigham and Women's Hospital
Boston, Massachusetts, 02115
St. Elizabeth's Medical Center
Boston, Massachusetts, 02135
MGH Cardiology
Boston, Massachusetts, 02214
Joslin Diabetes Center
Boston, Massachusetts, 02215
Connecticut Heart and Vascular Center
Bridgeport, Connecticut, 06606
Bridgeport Hospital
Bridgeport, Connecticut, 06610
Center for Advanced Medicine and Research LLC
Bridgeton, Missouri, 63044
Renu-Ca Research Institute, Lower Bucks Hospital
Bristol, Pennsylvania, 19007
Brown - SUNY Downstate Medical Center
Brooklyn, New York, 11203
Main Line Health Center, Broomall
Broomall, Pennsylvania, 19008
Buffalo Heart Group
Buffalo, New York, 14215
Burke Internal Medicine & Research
Burke, Virginia, 22015
Lahey Hospital and Medical Center
Burlington, Massachusetts, 01805
Spirit Physician Services, Inc
Camp Hill, Pennsylvania, 17011
Diabetes and Endocrinology Associates of Stark Cit
Canton, Ohio, 44718
IMD Medical Center
Carrollton, Texas, 75006
Texas Health Physicians Group
Carrollton, Texas, 75010
The Chambersburg Hospital
Chambersburg, Pennsylvania, 17201
Metrolina Internal Medicine
Charlotte, North Carolina, 28204
Gaffney Health Services
Charlotte, North Carolina, 28205
Carolinas Research Center
Charlotte, North Carolina, 28215
St. Mary's Medical Center
Charlotte Hall, Maryland, 20622
New Phase Research & Development
Chattanooga, Tennessee, 37409
Massachusetts General Hospital - Chelsea Health Care Center
Chelsea, Massachusetts, 02150
University of Chicago Medical Center
Chicago, Illinois, 60637
Advocate Med Group-Heart & Vascular Of Illinois
Chicago, Illinois, 60657
The Lindner Research Center
Cincinnati, Ohio, 45219
Center for Advanced Medicine and Research
City of Saint Peters, Missouri, 63303
St. Francis Medical Institute
Clearwater, Florida, 33765
Cleveland Clinic
Cleveland, Ohio, 44195
Calvert Memorial Hospital
Clinton, Maryland, 20735
Munni R. Selagamsetty, Md, Pc
Colorado Springs, Colorado, 80910
Clinical Research Center University of Missouri
Columbia, Missouri, 65212
South Carolina Heart Center
Columbia, South Carolina, 29204
Amistad Research Center, LLC
Columbia, South Carolina, 29223
Optimed Research, LTD
Columbus, Ohio, 43235
Bassett Healthcare Network
Cooperstown, New York, 13326
Gonzalez MD & Aswad MD Health Ser
Coral Gables, Florida, 33134
NYU Hudson Valley Cardiology
Cortlandt Manor, New York, 10567
Samaritan Health Services
Corvallis, Oregon, 97330
Heart Vascular of Northern Arizona
Cottonwood, Arizona, 86326
Dorothy H. Banish, MD, APMC Study Group
Covington, Louisiana, 70433
Avant Research Associates, LLC
Crowley, Louisiana, 70526
Medical Group of Culver City
Culver City, California, 90230
Partners in Clinical Research
Cumberland, Rhode Island, 02864
Atlanta Heart Specialists, LLC
Cumming, Georgia, 30041
American Research Institute, Inc.
Cutler Bay, Florida, 33157
Cardiovascular Research Institute of Dallas
Dallas, Texas, 75231
North Texas Health Center
Dallas, Texas, 75231
The Heart Center of Dallas
Dallas, Texas, 75235
Heart and Rhythm Specialists
Dalton, Georgia, 30720
Dayton Heart Center
Dayton, Ohio, 45414
Dayton Veteran Affairs Medical Center
Dayton, Ohio, 45428
Daytona Heart Group
Daytona Beach, Florida, 32114
Daytona Heart Group
DeLand, Florida, 32720
Seidman Clinical Trials
Delray Beach, Florida, 33484
Steven Cohen MD
Delray Beach, Florida, 33484
Vijay - Aurora Denver Cardiology
Denver, Colorado, 80218
Global Medical Research
DeSoto, Texas, 75115
John D. Dingell Veterans Affairs Medical Center
Detroit, Michigan, 48201
Trace Research Group at Wayne State University
Detroit, Michigan, 48201
Henry Ford Hospital
Detroit, Michigan, 48202
Infinite Clinical Research
Doral, Florida, 33126
International Research Partners, LLC
Doral, Florida, 33166
Medical Research Institute at Doral, Inc.
Doral, Florida, 33178
Central Bucks Cardiology
Doylestown, Pennsylvania, 18901
Altoona Center for Clinical Research
Duncansville, Pennsylvania, 16635
Albert F. Johary MD, PC
Dunwoody, Georgia, 30338
Cardiospecialists, LTD
Dyer, Indiana, 46311
Eastern Carolina Cardiovascular, PA
Elizabeth City, North Carolina, 27909
Heart Specialists of Lancaster County
Ephrata, Pennsylvania, 17522
Saint Vincent Consultants in Cardiovascular Diseases, LLC
Erie, Pennsylvania, 16502
Lake Internal Medicine Assocaties
Eustis, Florida, 32726
Martin - Martin Family Practice and Research
Evansville, Indiana, 47714
Touro University California- Solano County Affiliated Clinics
Fairfield, California, 94533
Seven Corners Medical Research Center
Falls Church, Virginia, 22044
Parkway Medical Group
Fayetteville, Tennessee, 37334
Feasterville Family Healthcare Center
Feasterville, Pennsylvania, 19053
Quantum Research LLC
Festus, Missouri, 63028
Family Health at Mount Olive
Flanders, New Jersey, 07836
Flint Clinical Research
Flint, Michigan, 48503
Apex Medical Research MI, Inc.
Flint, Michigan, 48504
NYHQ
Flushing, New York, 11355
Colorado Health Medical Group Heart Center of the Rockies
Fort Collins, Colorado, 80528
Medical Center of the Rockies Research
Fort Collins, Colorado, 80528
Invesclinic
Fort Lauderdale, Florida, 33308
Primary Care Associates
Fort Myers, Florida, 33907
Lee Physician Group
Fort Myers, Florida, 33908
Appalachian Research Associates
Fort Payne, Alabama, 35967
The Medical Group of Texas
Fort Worth, Texas, 76104
Texas Health Physicians Group
Fort Worth, Texas, 76107
University Of California San Francisco
Fresno, California, 93701
VACCHCS
Fresno, California, 93703
The Cardiac and Vascular Institute
Gainesville, Florida, 32605
University of Florida
Gainesville, Florida, 32610
Garden City Hospital
Garden City, Michigan, 48135
Stern Cardiovascular Foundation, Inc.
Germantown, Tennessee, 38138
Christiana Care Health System
Glen Mills, Pennsylvania, 19342
Genesys Regional Medical Center
Grand Blanc, Michigan, 48439
Altru Health System Rehab Center
Grand Forks, North Dakota, 58201
Great Falls Clinic Clinical Research Deptartment
Great Falls, Montana, 59420
Cardiology Associates of Bellin Health
Green Bay, Wisconsin, 54115
Eastern Cardiology
Greenville, North Carolina, 27834
Gulfside Clinical Research, LLC
Gulfport, Mississippi, 39501
Avant Research Associates, LLC
Guntersville, Alabama, 35976
T&R Clinic, P.A.
Haltom City, Texas, 76117
North Oaks Cardiology
Hammond, Louisiana, 70403
Hampton Family Practice Research
Hampton, Virginia, 23666
Tidewater Physicians Multispecialty Group
Hampton, Virginia, 23666
National Clinical LLC
Hamtramck, Michigan, 48212
Pinnacle Health Cardiovascular Institute
Harrisburg, Pennsylvania, 17110
Pentucket Medical Associates, Inc.
Haverhill, Massachusetts, 01830
Qway Research
Hialeah, Florida, 33010
State of the Art Research
Hialeah, Florida, 33010
Healing Touch C&C Research
Hialeah, Florida, 33012
Luzmed Clinical Research Institute
Hialeah, Florida, 33012
Viviana Perez MD Research & Cosmetics
Hialeah, Florida, 33012
Elite Cardiac Research Center LLC
Hialeah, Florida, 33013
Nova Clinical Research Clinic
Hialeah, Florida, 33013
Best Quality Research, Inc.
Hialeah, Florida, 33016
Cardiocare
Hillsborough, New Jersey, 08844
South Florida Research Solutions, LLC
Hollywood, Florida, 33021
John Gutleber Medical Research Office
Homestead, Florida, 33030
VA Pacific Islands Health Care System
Honolulu, Hawaii, 96819
Michele P. Sartori, MD
Houston, Texas, 77030
Saadat Ansari MD LLC
Huntsville, Alabama, 35801
Clinical Research Prime
Idaho Falls, Idaho, 83404
Midwest Cardiology Associates
Independence, Missouri, 64057
Krannert Institute Of Cardiology
Indianapolis, Indiana, 46202
Community Hospital South
Indianapolis, Indiana, 46227
Indiana Heart Physicians
Indianapolis, Indiana, 46237
Miller - SC Internal Medicine Associates.: Irmo
Irmo, South Carolina, 29063
University of MS Medical Center
Jackson, Mississippi, 39216
Kore Cardiovascular Research Institutue
Jackson, Tennessee, 38305
Jamaica Hospital Medical Center
Jamaica, New York, 11418
Freeman Health System
Joplin, Missouri, 64804
Cardiovascular Medical Associates of Palm Beach
Jupiter, Florida, 33458
VA Medical Center Kansas City
Kansas City, Missouri, 64128
Grand Medical Care
Katy, Texas, 77494
Team Research Of Central Texas
Killeen, Texas, 76543
Houston Heart and Vascular Associates
Kingwood, Texas, 77339
Hope Clinical Research
Kissimmee, Florida, 34758
SIH Research, LLC
Kissimmee, Florida, 34759
New Phase Research & Development
Knoxville, Tennessee, 37909
Cardiovascular Research of Knoxville
Knoxville, Tennessee, 37917
UCSD Sulpizio Cardiovascular Center
La Jolla, California, 92037
University Of California San Diego
La Jolla, California, 92093
Desert Medical Care & Wellness
La Quinta, California, 92253
Barrett Clinic, P.C.
La Vista, Nebraska, 68128
Kumar Medical Corporation
Lancaster, California, 93534
Colonnade Medical Group
Lancaster, Ohio, 43130
George Isajiw, MD
Lansdowne, Pennsylvania, 19050
Internal Medicine Clinic
Las Vegas, Nevada, 89102
Red Rock Clinical Research, LLC
Las Vegas, Nevada, 89146
Utah Cardiology, P.C.
Layton, Utah, 84041
VA Central Western Massachusetts Healthca
Leeds, Massachusetts, 01053
Northside Clinical Research
Lenoir, North Carolina, 28645
University of Kentucky
Lexington, Kentucky, 40536
Ocean State Clinical Research Prtnr
Lincoln, Rhode Island, 02865
New Jersey Heart
Linden, New Jersey, 07063
Unity Clinical Research
Lindsay, Oklahoma, 73052
Arkansas Cardiology
Little Rock, Arkansas, 72205
Arkansas Heart Hospital
Little Rock, Arkansas, 72211
Loma Linda University Health
Loma Linda, California, 92354
VA Loma Linda Healthcare System
Loma Linda, California, 92357
Long Beach Center for Clinical Research
Long Beach, California, 90807
Cardiovascular Innovation and Research
Long Beach, California, 90813
Los Alamitos Cardiovascular
Los Alamitos, California, 90720
Faye Montegrande Md. Clinical Research
Los Angeles, California, 90004
Eastside Clinical Research Associates
Los Angeles, California, 90022
Salman Khan A. Medical Corporation
Los Angeles, California, 90033
University of Southern California
Los Angeles, California, 90033
West LA VA Medical Center
Los Angeles, California, 90049
Robley Rex VAMC
Louisville, Kentucky, 40202
Stoddard - University of Louisville
Louisville, Kentucky, 40202
Bays - L-MARC Research Center
Louisville, Kentucky, 40213
Dean Foundation
Madison, Wisconsin, 53715
University Of Wisconsin
Madison, Wisconsin, 53715
Virginia Cardiovascular Associates
Manassas, Virginia, 20109
Manassas Clinical Research Center
Manassas, Virginia, 20110
American Clinical Research, LLC
Marrero, Louisiana, 70072
Grace Research, LLC
Marshall, Texas, 75670
Marshfield Clinic
Marshfield, Wisconsin, 54449
VA Northern California Health Care
Mather, California, 95655
Valley Heart Consultants
McAllen, Texas, 78503
Tucker Cardiology Associates, P.C.
Mechanicsville, Virginia, 23116
Southern Oregon Cardiology, LLC
Medford, Oregon, 97504
Ramanathan - VAMC Memphis
Memphis, Tennessee, 38104
CardioVascular Associates of Mesa
Mesa, Arizona, 85206
Medical Research Center of Florida
Miami, Florida, 33122
LG Diagnostics, Inc.
Miami, Florida, 33126
St. Paul Medical Research Center, Inc.
Miami, Florida, 33126
Team Medical Research
Miami, Florida, 33134
Paradise Clinical Research, LLC
Miami, Florida, 33144
GAD Research Center
Miami, Florida, 33155
Innovation Research Institute, Inc.
Miami, Florida, 33155
Sanitas Research
Miami, Florida, 33155
Segui - Med Care Research
Miami, Florida, 33165
South Florida Research Group, LLC
Miami, Florida, 33176
Vista Health Research, LLC
Miami, Florida, 33176
D De La Vega MD Research Group
Miami, Florida, 33186
Lakes Research, LLC
Miami Lakes, Florida, 33014
Veritas Research Corp.
Miami Lakes, Florida, 33014
Ocean Blue Medical Research Center
Miami Springs, Florida, 33166
Middletown Cardiovascular Associates
Middletown, Ohio, 45044
South Shore Internal Medicine
Milton, Massachusetts, 02186
Columbia St. Mary's
Milwaukee, Wisconsin, 53211
Aurora St. Luke's Medical Center
Milwaukee, Wisconsin, 53215
Long Island Heart Associates
Mineola, New York, 11501
Winthrop University Hospital
Mineola, New York, 11501
Heart Center, Palo Pinto General Hospital
Mineral Wells, Texas, 76067
Valley Central Research Inc
Mission, Texas, 78572
Cone - Montana Medical Research
Missoula, Montana, 59801
University of South Alabama: Division of Clinical Research
Mobile, Alabama, 36617
Lake Shore Clinical Research, LLC.
Mooresville, North Carolina, 28117
Carteret Medical Group
Morehead City, North Carolina, 28557
Cardiology Associates of Carolinas, PA
Morganton, North Carolina, 28655
Bucks County Clinical Research
Morrisville, Pennsylvania, 19067
Medical Consultants, PC
Muncie, Indiana, 47303
Southwest Florida Research, LLC
Naples, Florida, 34102
Lahey Cardiology
Nashua, New Hampshire, 03060
Clinical Research Center Meharry Medical College
Nashville, Tennessee, 37208
Otis Barnum D.O.P.C.
Natchitoches, Louisiana, 71457
Jersey Shore University Medical Center
Neptune City, New Jersey, 07753
Eastern Nephrology Associates, PLLC
New Bern, North Carolina, 28562
Cardiovascular Institute
New Brunswick, New Jersey, 08901
Long Island Jewish Medical Center
New Hyde Park, New York, 11040
Queens Long Island Medical Group
New Hyde Park, New York, 11577
Tulane University Office of Health Research
New Orleans, Louisiana, 70112
Chinatown Cardiology, PC
New York, New York, 10013
Weill Cornell Medical College and NY Presbyterian
New York, New York, 10021
Mount Sinai School of Medicine
New York, New York, 10029
Cardiology Physicians/Red Clay Research
Newark, Delaware, 19713
TPMG Clinical Research
Newport News, Virginia, 23606
Sentara Norfolk General Hospital
Norfolk, Virginia, 23507
Illinois Heart & Lung Research Center, SC
Normal, Illinois, 61761
Palisade Medical Center
North Bergen, New Jersey, 07047
Captain James A. Lovell Federal Health
North Chicago, Illinois, 60064
DiGiovanna Institute for Medical Education and Research
North Massapequa, New York, 11758
North Hills Medical Research, Inc
North Richland Hills, Texas, 76180
Valley Clinical Trials, Inc.
Northridge, California, 91325
COR Clinical Research, LLC
Oklahoma City, Oklahoma, 73103
Thadani - VA Medical Center Oklahoma City, OK
Oklahoma City, Oklahoma, 73104
Today Clinical Research
Oklahoma City, Oklahoma, 73129
Cardiovascular Health Clinic
Oklahoma City, Oklahoma, 73134
Charlotte Hearts
Old Point Station, South Carolina, 29707
Specialty Physicians of Illinois, LLC
Olympia Fields, Illinois, 60461
Heart Consultants
Omaha, Nebraska, 68114
Alegent Creighton Health
Omaha, Nebraska, 68131
University of Nebraska Medical Center
Omaha, Nebraska, 68198
Orange County Heart Institute & Research
Orange, California, 92868
University of CA Irvine Medical Center
Orange, California, 92868
Orlando Healthy Heart Institute
Orlando, Florida, 32806
Lake Regional Cardiovascular Institute
Osage Beach, Missouri, 65065
Stahl - Midwest Heart & Vascular Specialists
Overland Park, Kansas, 66209
Research Integrity LLC
Owensboro, Kentucky, 42303
Diverse Research Solutions
Oxnard, California, 93030
Grace Research, LLC
Palestine, Texas, 75801
Palm Beach Gardens Research Center, LLC
Palm Beach Gardens, Florida, 33410
Unrein - Rocky Vista University Health Center
Parker, Colorado, 80134
Huntington Memorial Hospital
Pasadena, California, 91105
Inlet Cardiopulmonary & Associates
Pawleys Island, South Carolina, 29585
Memorial Hospital of Rhode Island
Pawtucket, Rhode Island, 02860
Lahey Medical Center
Peabody, Massachusetts, 02149
Broward Research Center
Pembroke Pines, Florida, 33024
Pioneer Clinical Research
Pembroke Pines, Florida, 33024
Sandoval - Broward Research Center
Pembroke Pines, Florida, 33204
Drexel University College of Medicine
Philadelphia, Pennsylvania, 19102
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104
Arizona Arthritis & Rheumatology Research
Phoenix, Arizona, 85032
Champlain Valley Physician Hospital
Plattsburgh, New York, 12901
Avant Research Associates, LLC
Port Arthur, Texas, 77640
Canada60 sites
Bramalea Medical Centre
Brampton, Ontario, L6T 4S5
Brampton Research Associates
Brampton, Ontario, L6Z 4N5
Viacar Recherche Clinique Inc.
Brossard, Quebec, J4X1S4
Philippe R Beaudry Medicine Professional Corporation
Burlington, Ontario, L7R 4E2
Vizel Cardiac Research
Cambridge, Ontario, N1R7R1
Dr. Linda Sinnaeve's Office
Chatham, Ontario, N7L 1C1
Ecogene-21
Chicoutimi, Quebec, G7H 7K9
Q&T Research Chicoutimi
Chicoutimi, Quebec, G7H 7Y8
Scisco Clinical Research
Cornwall, Ontario, K6H 4M4
G.S. Cardiac Lab Medicine Professional Corp
Greater Sudbury, Ontario, P3C 1S8
Dr. R. Labonte Professional Med Corp
Greater Sudbury, Ontario, P3E 3B8
Dr. G. Garrioch, Independent Practice
Greater Sudbury, Ontario, P3E 3C6
Viacar Recherche Clinique Inc.
Greenfield Park, Quebec, J4V2G8
Dr. Peter Spadafora Health Center
Guelph, Ontario, N1E 5G6
John Stimac, MD
Hamilton, Ontario, L8L 5G4
KMH Cardiology & Diagnostics: Hamilton
Hamilton, Ontario, L8P 3A9
Dr. William Liang
Hamilton, Ontario, L8W3J6
Source Unique Clinic
Hawkesbury, Ontario, K6A 1A1
Dr. Ronald Fowlis
Kitchener, Ontario, N2M 5NG
University Hospital
London, Ontario, N6A 5A5
Malton Medical Research
Mississauga, Ontario, L4T 4J2
KMH Cardiology & Diagnostics: Mississauga
Mississauga, Ontario, L5K 2L3
Sewa Ram Singal Medicine Professional Corporation
Mississauga, Ontario, L5U 0A6
CHUM Hotel-Dieu
Montreal, Quebec, H2W 1T8
Newmarket Cardiology Research Group
Newmarket, Ontario, l3y -8c3
Newmarket Cardiology Research Group
Newmarket, Ontario, L3Y 8C3
Portage Medical Centre
Niagara Falls, Ontario, I2E6A6
The Medical Arts Health Research Group
North Vancouver, British Columbia, V7M 2H4
Humber River Regional Hospital
North York, Ontario, M3N2V6
Bakbak Medicine Professional Corporation
Oshawa, Ontario, L1H 1B9
Dr. James Y. Cha
Oshawa, Ontario, L1J2K1
University Of Ottawa Heart Institute
Ottawa, Ontario, k1y -4w7
The Medical Arts Health Research Group
Penticton, British Columbia, V2A 5C8
Kawartha Cardiology Clinical Trials
Peterborough, Ontario, K9J0B2
Steeple Hill Medical Centre
Pickering, Ontario, L1V 2A6
Recherche Clinique Sigma, Inc.
Québec, Quebec, G1G3Z4
Iucpq
Québec, Quebec, G1V 4G5
ALPHA Recherche Clinique
Québec, Quebec, G3K 2P8
CardioVasc HR
Saint-Jean-sur-Richelieu, Quebec, j3a-1c3
ViaCar Recherche Clinique Inc
Saint-Lambert, Quebec, J4P 2H4
Viacar Recherche Clinique
Saint-Lambert, Quebec, J4P 2J2
Sarnia Institute Of Clinical Research
Sarnia, Ontario, N7T 4X3
Scarborough Cardiology Research
Scarborough Village, Ontario, M1E5E9
Scarborough General Hospital Cardiology Research Associates
Scarborough Village, Ontario, M1PT27
Milliken Medical Centre
Scarborough Village, Ontario, M1V5P6
Canadian Centre for Research on Diabetes
Smith Falls, Ontario, K7A 4W8
Lake Shore Cardiology
St. Catharines, Ontario, L2S 2Y3
Sardar Medical Clinic
St. Thomas, Ontario, N5R 2R4
Hopital Pierre-Le Gardeur
Terrebonne, Quebec, J6V 2H2
Dr. Laurence Gibbs Medicine Professional Corp.
Thedford, Ontario, N0M 2N0
Tillsonburg Medical Centre
Tillsonburg, Ontario, N4G 5A7
Humber River Hospital
Toronto, Ontario, M3M 0B2
Sunnybrook Health Sciences Centre
Toronto, Ontario, M4N 3M5
St. Michael's Hospital
Toronto, Ontario, M5B 1W8
Mount Sinai Hospital
Toronto, Ontario, M5G 1X5
Toronto General Hospital
Toronto, Ontario, M5G 2N2
Weston Road Medical Clinic
Toronto, Ontario, M9N 2A7
Dr. Nigel Jagan Medicine Professional Corporation
Whitby, Ontario, L1N 2L1
Dr. Nwadiaro Medicine Professional Corp
Windsor, Ontario, N8X 1L9
Winnipeg Clinic
Winnipeg, Manitoba, R3C 0N2
Puerto Rico6 sites
Instituto Sanacoop
Bayamón, 00961
San Juan Bautista School of Medicine
Caguas, 00727
Norma S. Severino-Pacheco, MD
Canovanas, 00729
Cardiometabolic Research Center
Ponce, 00717
Miguel Sosa-Padilla, MD
San Juan, 00926-2832
Yolanda Sierra Quinones, MD
Toa Baja, 00949
About this study
Official title: A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
The Cardiovascular Inflammation Reduction Trial (CIRT) is a randomized clinical trial investigating whether taking low-dose methotrexate reduces heart attacks, strokes, or death in people with type 2 diabetes or metabolic syndrome that have had a heart attack or multiple coronary blockages. This trial is funded by the National Heart, Lung, and Blood Institute (NHLBI)/National Institutes of Health (NIH).
Read the detailed description
While inflammation contributes crucially to atherothrombosis, it is unknown whether inhibition of inflammation per se will lower vascular event rates. The primary aim of the Cardiovascular Inflammation Reduction Trial (CIRT) is to directly test the inflammatory hypothesis of atherothrombosis by evaluating whether or not low-dose methotrexate (LDM) will reduce rates of myocardial infarction, stroke, and cardiovascular death among stable coronary artery disease patients with type 2 diabetes or metabolic syndrome, conditions associated with an enhanced pro-inflammatory response. CIRT is a randomized, double-blind, placebo-controlled, multi-center, event-driven trial that will randomize 7,000 men and women from the United States and Canada. Following a five- to six-week open-label run-in (maximum 8 weeks), eligible participants who have either suffered documented myocardial infarction in the past or have angiographically demonstrated multivessel coronary artery disease in the past will be randomly allocated over a three to four year period to usual care plus placebo or usual care plus LDM. The target methotrexate dose among those allocated to active therapy is 15 to 20 mg po per week, a dose within the range of that commonly used for the treatment of rheumatoid arthritis. All study participants will additionally receive 1.0 mg oral folate to be taken daily six days per week. LDM complications will be minimized through education programs for all investigators and coordinators, through enhanced communication with study participants, by limiting enrollment to those with no evidence of malignancy, hepatitis, renal dysfunction, chronic infection, pulmonary disease, or other risk factors for toxicity; by conducting an initial 5- to 6-week active-therapy run-in (maximum 8 weeks) designed to eliminate individuals who are either intolerant of or unable to adhere to treatment before randomization; and through regular monitoring of liver function and hematologic indices using a centralized methodology designed to ensure participant safety, allow for dose adjustments while maintaining the study blind, and provide an efficient method to address issues of compliance and follow-up on a cost-effective centralized basis. The primary trial endpoint is the rate of myocardial infarction, stroke, or cardiovascular death. Secondary and tertiary endpoints include all-cause mortality, coronary revascularization, incident congestive heart failure, incident peripheral artery disease, incident venous thrombosis, clinically significant aortic stenosis, incident atrial fibrillation, incident diabetes among those with metabolic syndrome but not diabetes at study entry, and hemoglobin A1c (HbA1c) control among those with diabetes at study entry. The trial is event driven such that in the absence of extreme effects, the trial will conclude after accrual of at least 530 primary endpoints, an effect estimated to provide 90 percent power to detect a 25 percent relative risk reduction. The potential clinical impact of CIRT is broad as it has sufficient power to directly address core issues in the inflammatory hypothesis of atherothrombosis, and thus, if successful, will open major new directions for cardiovascular treatment.
- Conditions
- Cardiovascular Disease
- Being tested
- Methotrexate, Placebo
- Keywords
- Myocardial Infarction, Stroke, Cardiovascular death, Type 2 Diabetes, Metabolic Syndrome, Cardiovascular Inflammation, Atherothrombosis
- Medical subject headings
- Cardiovascular Diseases, Myocardial Infarction, Stroke, Diabetes Mellitus, Type 2, Metabolic Syndrome, Thrombosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MethotrexateDrug
Also called Trexall, TEVA Inc (brand of methotrexate)
Tablet, Oral, Target dose 15-20 mg weekly plus 1.0 mg folic acid 6 days/week
PlaceboDrug
Tablet, Oral, weekly plus 1.0 mg folic acid 6 days/week
| Study group | Role | What they receive |
|---|---|---|
| Methotrexate | Experimental | Methotrexate: Tablet, Oral, Target dose 15-20mg weekly plus 1.0 mg folic acid 6 days/week Receives: Drug: Methotrexate |
| Placebo | Placebo comparator | Placebo: Tablet, Oral weekly plus 1.0mg folic acid 6 days/week Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Subjects With Major Adverse Cardiovascular Events
The first occurrence of Major Adverse Cardiovascular Event which is defined as the occurrence of one or more of the following: Cardiovascular Death, Non-Fatal Myocardial Infarction or Non-Fatal Stroke.
Measured: From randomization to trial end (April 2, 2018) up to a maximum of 5 years
Number of Subjects With Major Adverse Cardiovascular Event or Hospitalization for Unstable Angina That Led to Urgent Coronary Revascularization
The first occurrence of Major Adverse Cardiovascular Event or Hospitalization for Unstable Angina that led to Urgent Coronary Revascularization.
Measured: From randomization to trial end (April 2, 2018) - up to a maximum of 5 years
Secondary outcomes (5)
Number of Subjects With All-cause Mortality
Subjects who died from any cause.
Measured: From randomization to the trial end (April 2, 2018) up to a maximum of 5 years
Number of Subjects With Major Adverse Cardiovascular Event or Any Coronary Revascularization
The first occurrence of Major Adverse Cardiovascular Event or Any Coronary Revascularization.
Measured: From randomization to the trial end (April 2, 2018) - up to a maximum of 5 years
Number of Subjects With Hospitalization for Congestive Heart Failure
The first occurrence of Hospitalization for Congestive Heart Failure
Measured: From randomization to trial end (April 2, 2018) up to a maximum of 5 years
Number of Subjects With Major Adverse Cardiovascular Event, Coronary Revascularization, Hospitalization for Congestive Heart Failure or All Cause Mortality
The first occurrence of Major Adverse Cardiovascular Event, Coronary Revascularization, Hospitalization for Congestive Heart Failure or All Cause Mortality.
Measured: From randomization to trial end (April 2, 2018) up to a maximum of 5 years
Number of Subjects With New Onset Type 2 Diabetes
New onset type 2 diabetes among those without diabetes at baseline. Baseline diabetes is defined as any of the following prior to randomization: clinician report of diabetes, use of antidiabetic medication, hbA1c >=6.5 or fasting plasma glucose >=126.
Measured: From randomization to the trial end (April 2, 2018) - up to 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 May 2012 (estimated)
- Study startApr 2013
- Primary completion15 Apr 2019
- Study completion30 Oct 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (11)Papers the sponsor has linked to this study.
- Other trials for Cardiovascular DiseaseStudies of the same condition, open and under way.
- More trials run by Brigham and Women's HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 4,786 participants (actual)
Sponsor and investigators
- Lead sponsor
- Brigham and Women's Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- National Heart, Lung, and Blood Institute (NHLBI)
- Responsible party
- Principal investigator, Paul Ridker, Brigham and Women's Hospital
- Investigators
- Paul Ridker, MD, MPH, Principal investigator, Brigham and Women's Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01594333
- Sponsor's protocol ID
- 2012P-000857
- Other IDs
- U01HL101422, U01HL101389
- Acronym
- CIRT
- Status last verified
- Jul 2020
- First submitted
- 1 May 2012
- Last updated
- 24 Jul 2020
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
Publications
Cui J, Ridker PM, Solomon DH. Blood pressure changes during methotrexate treatment: results from a randomized placebo-controlled trial among patients with cardiovascular risk. Rheumatology (Oxford). 2025 Jun 1;64(6):3917-3920. doi: 10.1093/rheumatology/keae604.
PubMed 39657237Cui J, Di Martino V, Solomon DH. Longitudinal Follow-Up of Fibrosis-4 in Patients at Risk of Metabolic Dysfunction-Associated Steatotic Liver Disease Receiving Low-Dose Methotrexate Treatment. Clin Gastroenterol Hepatol. 2024 Nov;22(11):2337-2339. doi: 10.1016/j.cgh.2024.03.035. Epub 2024 Apr 24.
PubMed 38663834Cui J, Chasman DI, Raychaudhuri S, Xu C, Ridker PM, Solomon DH, Karlson EW. Genetics are not likely to offer clinically useful predictions for elevated liver enzyme levels in patients using low dose methotrexate. Semin Arthritis Rheum. 2022 Aug;55:152036. doi: 10.1016/j.semarthrit.2022.152036. Epub 2022 May 28.
PubMed 35671649Reiss AB, Teboul I, Kasselman L, Ahmed S, Carsons SE, De Leon J. Methotrexate effects on adenosine receptor expression in peripheral monocytes of persons with type 2 diabetes and cardiovascular disease. J Investig Med. 2022 Aug;70(6):1433-1437. doi: 10.1136/jim-2022-002355. Epub 2022 May 23.
PubMed 35606100Sparks JA, Vanni KMM, Sparks MA, Xu C, Santacroce LM, Glynn RJ, Ridker PM, Solomon DH. Effect of Low-Dose Methotrexate on eGFR and Kidney Adverse Events: A Randomized Clinical Trial. J Am Soc Nephrol. 2021 Dec 1;32(12):3197-3207. doi: 10.1681/ASN.2021050598. Epub 2021 Dec 1.
PubMed 34551998Xu C, Selhub J, Jacques P, Paynter NP, MacFadyen JG, Glynn RJ, Ridker PM, Solomon DH. Adverse effects related to methotrexate polyglutamate levels: adjudicated results from the cardiovascular inflammation reduction trial. Rheumatology (Oxford). 2021 Jun 18;60(6):2963-2968. doi: 10.1093/rheumatology/keaa650.
PubMed 34144603Sparks JA, Dellaripa PF, Glynn RJ, Paynter NP, Xu C, Ridker PM, Solomon DH. Pulmonary Adverse Events in Patients Receiving Low-Dose Methotrexate in the Randomized, Double-Blind, Placebo-Controlled Cardiovascular Inflammation Reduction Trial. Arthritis Rheumatol. 2020 Dec;72(12):2065-2071. doi: 10.1002/art.41452. Epub 2020 Oct 7.
PubMed 32741143Ridker PM, MacFadyen JG, Glynn RJ, Bradwin G, Hasan AA, Rifai N. Comparison of interleukin-6, C-reactive protein, and low-density lipoprotein cholesterol as biomarkers of residual risk in contemporary practice: secondary analyses from the Cardiovascular Inflammation Reduction Trial. Eur Heart J. 2020 Aug 14;41(31):2952-2961. doi: 10.1093/eurheartj/ehaa160.
PubMed 32221587Solomon DH, Glynn RJ, Karlson EW, Lu F, Corrigan C, Colls J, Xu C, MacFadyen J, Barbhaiya M, Berliner N, Dellaripa PF, Everett BM, Pradhan AD, Hammond SP, Murray M, Rao DA, Ritter SY, Rutherford A, Sparks JA, Stratton J, Suh DH, Tedeschi SK, Vanni KMM, Paynter NP, Ridker PM. Adverse Effects of Low-Dose Methotrexate: A Randomized Trial. Ann Intern Med. 2020 Mar 17;172(6):369-380. doi: 10.7326/M19-3369. Epub 2020 Feb 18.
PubMed 32066146Ridker PM, Everett BM, Pradhan A, MacFadyen JG, Solomon DH, Zaharris E, Mam V, Hasan A, Rosenberg Y, Iturriaga E, Gupta M, Tsigoulis M, Verma S, Clearfield M, Libby P, Goldhaber SZ, Seagle R, Ofori C, Saklayen M, Butman S, Singh N, Le May M, Bertrand O, Johnston J, Paynter NP, Glynn RJ; CIRT Investigators. Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. N Engl J Med. 2019 Feb 21;380(8):752-762. doi: 10.1056/NEJMoa1809798. Epub 2018 Nov 10.
PubMed 30415610Everett BM, Pradhan AD, Solomon DH, Paynter N, Macfadyen J, Zaharris E, Gupta M, Clearfield M, Libby P, Hasan AA, Glynn RJ, Ridker PM. Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. Am Heart J. 2013 Aug;166(2):199-207.e15. doi: 10.1016/j.ahj.2013.03.018. Epub 2013 May 3.
PubMed 23895801
Study at a glance
From the registry record, last updated by the sponsor on 24 Jul 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
- ClinicalTrials.gov ID
- NCT01594333
- Acronym / sponsor ID
- CIRT / 2012P-000857
- Conditions
- Cardiovascular Disease
- Keywords
- Myocardial Infarction, Stroke, Cardiovascular death, Type 2 Diabetes, Metabolic Syndrome, Cardiovascular Inflammation, Atherothrombosis
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 4,786 participants (actual)
- Lead sponsor
- Brigham and Women's HospitalUniversity, hospital or other
- Collaborators
- National Heart, Lung, and Blood Institute (NHLBI)
- Study start
- Apr 2013
- Primary completion
- 15 Apr 2019 (actual)
- Study completion
- 30 Oct 2019 (actual)
- First posted
- 9 May 2012 (estimated)
- Results
- Posted 24 Jul 2020
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The Cardiovascular Inflammation Reduction Trial (CIRT) is a randomized clinical trial investigating whether taking low-dose methotrexate reduces heart attacks, strokes, or death in people with type 2 diabetes or metabolic syndrome that have had a heart attack or multiple coronary blockages. This trial is funded by the National Heart, Lung, and Blood Institute (NHLBI)/National Institutes of Health (NIH).
Detailed description
While inflammation contributes crucially to atherothrombosis, it is unknown whether inhibition of inflammation per se will lower vascular event rates. The primary aim of the Cardiovascular Inflammation Reduction Trial (CIRT) is to directly test the inflammatory hypothesis of atherothrombosis by evaluating whether or not low-dose methotrexate (LDM) will reduce rates of myocardial infarction, stroke, and cardiovascular death among stable coronary artery disease patients with type 2 diabetes or metabolic syndrome, conditions associated with an enhanced pro-inflammatory response. CIRT is a randomized, double-blind, placebo-controlled, multi-center, event-driven trial that will randomize 7,000 men and women from the United States and Canada. Following a five- to six-week open-label run-in (maximum 8 weeks), eligible participants who have either suffered documented myocardial infarction in the past or have angiographically demonstrated multivessel coronary artery disease in the past will be randomly allocated over a three to four year period to usual care plus placebo or usual care plus LDM. The target methotrexate dose among those allocated to active therapy is 15 to 20 mg po per week, a dose within the range of that commonly used for the treatment of rheumatoid arthritis. All study participants will additionally receive 1.0 mg oral folate to be taken daily six days per week. LDM complications will be minimized through education programs for all investigators and coordinators, through enhanced communication with study participants, by limiting enrollment to those with no evidence of malignancy, hepatitis, renal dysfunction, chronic infection, pulmonary disease, or other risk factors for toxicity; by conducting an initial 5- to 6-week active-therapy run-in (maximum 8 weeks) designed to eliminate individuals who are either intolerant of or unable to adhere to treatment before randomization; and through regular monitoring of liver function and hematologic indices using a centralized methodology designed to ensure participant safety, allow for dose adjustments while maintaining the study blind, and provide an efficient method to address issues of compliance and follow-up on a cost-effective centralized basis. The primary trial endpoint is the rate of myocardial infarction, stroke, or cardiovascular death. Secondary and tertiary endpoints include all-cause mortality, coronary revascularization, incident congestive heart failure, incident peripheral artery disease, incident venous thrombosis, clinically significant aortic stenosis, incident atrial fibrillation, incident diabetes among those with metabolic syndrome but not diabetes at study entry, and hemoglobin A1c (HbA1c) control among those with diabetes at study entry. The trial is event driven such that in the absence of extreme effects, the trial will conclude after accrual of at least 530 primary endpoints, an effect estimated to provide 90 percent power to detect a 25 percent relative risk reduction. The potential clinical impact of CIRT is broad as it has sufficient power to directly address core issues in the inflammatory hypothesis of atherothrombosis, and thus, if successful, will open major new directions for cardiovascular treatment.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Methotrexate | Experimental | Drug: MethotrexateMethotrexate: Tablet, Oral, Target dose 15-20mg weekly plus 1.0 mg folic acid 6 days/week |
| Placebo | Placebo comparator | Drug: PlaceboPlacebo: Tablet, Oral weekly plus 1.0mg folic acid 6 days/week |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Age ≥ 18 years at screening
- Documented past history of myocardial infarction OR past evidence of multivessel coronary artery disease by angiography.
- History of type 2 diabetes or metabolic syndrome at time of study enrollment
- Willingness to participate as evidenced by signing the study informed consent
Key exclusion criteria (13 listed)
- Prior history of chronic infectious disease, tuberculosis, or severe fungal disease; chronic hepatitis B or C infection; renal insufficiency; interstitial pneumonitis, bronchiectasis, or pulmonary fibrosis; known chronic pericardial effusion, pleural effusion, or ascites; chronic liver disease; myeloproliferative disorders in the past 5 years; non-basal cell malignancy or treated lymphoproliferative disease within the past 5 years; known HIV positive; life expectancy of < 3 years;
- Chronic inflammatory condition such as lupus or rheumatoid arthritis, ulcerative colitis or Crohn's disease
- White blood cell count < 3,500/ul, hematocrit < 32 percent, or platelet count < 75,000/ul
- Liver transaminase levels (AST or ALT) >upper limit of normal (ULN) or albumin < the lower limit of normal (LLN);
- Creatinine clearance < 40 ml/min as estimated with the Cockcroft-Gault equation;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MethotrexateAlso: Trexall, TEVA Inc (brand of methotrexate)Tablet, Oral, Target dose 15-20 mg weekly plus 1.0 mg folic acid 6 days/week | Drug | Methotrexate |
| PlaceboTablet, Oral, weekly plus 1.0 mg folic acid 6 days/week | Drug | Placebo |
Primary outcome
Number of Subjects With Major Adverse Cardiovascular Events
Time frame: From randomization to trial end (April 2, 2018) up to a maximum of 5 years
The first occurrence of Major Adverse Cardiovascular Event which is defined as the occurrence of one or more of the following: Cardiovascular Death, Non-Fatal Myocardial Infarction or Non-Fatal Stroke.
Number of Subjects With Major Adverse Cardiovascular Event or Hospitalization for Unstable Angina That Led to Urgent Coronary Revascularization
Time frame: From randomization to trial end (April 2, 2018) - up to a maximum of 5 years
The first occurrence of Major Adverse Cardiovascular Event or Hospitalization for Unstable Angina that led to Urgent Coronary Revascularization.
5 secondary outcomes
Number of Subjects With All-cause Mortality
Time frame: From randomization to the trial end (April 2, 2018) up to a maximum of 5 years
Number of Subjects With Major Adverse Cardiovascular Event or Any Coronary Revascularization
Time frame: From randomization to the trial end (April 2, 2018) - up to a maximum of 5 years
Number of Subjects With Hospitalization for Congestive Heart Failure
Time frame: From randomization to trial end (April 2, 2018) up to a maximum of 5 years
Number of Subjects With Major Adverse Cardiovascular Event, Coronary Revascularization, Hospitalization for Congestive Heart Failure or All Cause Mortality
Time frame: From randomization to trial end (April 2, 2018) up to a maximum of 5 years
Number of Subjects With New Onset Type 2 Diabetes
Time frame: From randomization to the trial end (April 2, 2018) - up to 5 years
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Jul 2020.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 39657237Cui J, Ridker PM, Solomon DH. Blood pressure changes during methotrexate treatment: results from a randomized placebo-controlled trial among patients with cardiovascular risk. Rheumatology (Oxford). 2025 Jun 1;64(6):3917-3920. doi: 10.1093/rheumatology/keae604.
- Derived from this study: PubMed 38663834Cui J, Di Martino V, Solomon DH. Longitudinal Follow-Up of Fibrosis-4 in Patients at Risk of Metabolic Dysfunction-Associated Steatotic Liver Disease Receiving Low-Dose Methotrexate Treatment. Clin Gastroenterol Hepatol. 2024 Nov;22(11):2337-2339. doi: 10.1016/j.cgh.2024.03.035. Epub 2024 Apr 24.
- Derived from this study: PubMed 35671649Cui J, Chasman DI, Raychaudhuri S, Xu C, Ridker PM, Solomon DH, Karlson EW. Genetics are not likely to offer clinically useful predictions for elevated liver enzyme levels in patients using low dose methotrexate. Semin Arthritis Rheum. 2022 Aug;55:152036. doi: 10.1016/j.semarthrit.2022.152036. Epub 2022 May 28.
- Derived from this study: PubMed 35606100Reiss AB, Teboul I, Kasselman L, Ahmed S, Carsons SE, De Leon J. Methotrexate effects on adenosine receptor expression in peripheral monocytes of persons with type 2 diabetes and cardiovascular disease. J Investig Med. 2022 Aug;70(6):1433-1437. doi: 10.1136/jim-2022-002355. Epub 2022 May 23.
- Derived from this study: PubMed 34551998Sparks JA, Vanni KMM, Sparks MA, Xu C, Santacroce LM, Glynn RJ, Ridker PM, Solomon DH. Effect of Low-Dose Methotrexate on eGFR and Kidney Adverse Events: A Randomized Clinical Trial. J Am Soc Nephrol. 2021 Dec 1;32(12):3197-3207. doi: 10.1681/ASN.2021050598. Epub 2021 Dec 1.
- Derived from this study: PubMed 34144603Xu C, Selhub J, Jacques P, Paynter NP, MacFadyen JG, Glynn RJ, Ridker PM, Solomon DH. Adverse effects related to methotrexate polyglutamate levels: adjudicated results from the cardiovascular inflammation reduction trial. Rheumatology (Oxford). 2021 Jun 18;60(6):2963-2968. doi: 10.1093/rheumatology/keaa650.
- Derived from this study: PubMed 32741143Sparks JA, Dellaripa PF, Glynn RJ, Paynter NP, Xu C, Ridker PM, Solomon DH. Pulmonary Adverse Events in Patients Receiving Low-Dose Methotrexate in the Randomized, Double-Blind, Placebo-Controlled Cardiovascular Inflammation Reduction Trial. Arthritis Rheumatol. 2020 Dec;72(12):2065-2071. doi: 10.1002/art.41452. Epub 2020 Oct 7.
- Derived from this study: PubMed 32221587Ridker PM, MacFadyen JG, Glynn RJ, Bradwin G, Hasan AA, Rifai N. Comparison of interleukin-6, C-reactive protein, and low-density lipoprotein cholesterol as biomarkers of residual risk in contemporary practice: secondary analyses from the Cardiovascular Inflammation Reduction Trial. Eur Heart J. 2020 Aug 14;41(31):2952-2961. doi: 10.1093/eurheartj/ehaa160.
- Derived from this study: PubMed 32066146Solomon DH, Glynn RJ, Karlson EW, Lu F, Corrigan C, Colls J, Xu C, MacFadyen J, Barbhaiya M, Berliner N, Dellaripa PF, Everett BM, Pradhan AD, Hammond SP, Murray M, Rao DA, Ritter SY, Rutherford A, Sparks JA, Stratton J, Suh DH, Tedeschi SK, Vanni KMM, Paynter NP, Ridker PM. Adverse Effects of Low-Dose Methotrexate: A Randomized Trial. Ann Intern Med. 2020 Mar 17;172(6):369-380. doi: 10.7326/M19-3369. Epub 2020 Feb 18.
- Derived from this study: PubMed 30415610Ridker PM, Everett BM, Pradhan A, MacFadyen JG, Solomon DH, Zaharris E, Mam V, Hasan A, Rosenberg Y, Iturriaga E, Gupta M, Tsigoulis M, Verma S, Clearfield M, Libby P, Goldhaber SZ, Seagle R, Ofori C, Saklayen M, Butman S, Singh N, Le May M, Bertrand O, Johnston J, Paynter NP, Glynn RJ; CIRT Investigators. Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. N Engl J Med. 2019 Feb 21;380(8):752-762. doi: 10.1056/NEJMoa1809798. Epub 2018 Nov 10.
- Derived from this study: PubMed 23895801Everett BM, Pradhan AD, Solomon DH, Paynter N, Macfadyen J, Zaharris E, Gupta M, Clearfield M, Libby P, Hasan AA, Glynn RJ, Ridker PM. Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. Am Heart J. 2013 Aug;166(2):199-207.e15. doi: 10.1016/j.ahj.2013.03.018. Epub 2013 May 3.
Related trials for Cardiovascular Disease
Enrolling by invitationObservational study
Multi-Scale Analysis of Phenotypes in Heart Failure (MAP-HEART)
Heart Failure
Recruiting
Delay AvoIding Primary Evaluation for ThRombectomy of Acute StrokE Patients With Large Vessel OCclusion in the Angiography SuiTe
Stroke, Acute
Active, not recruitingObservational study
REdo Transcatheter Aortic VALVE Implantation for the Management of Transcatheter Aortic Valve Failure
Aortic Valve Stenosis
RecruitingPhase 1/2
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Relapsed/Refractory Multiple Myeloma
RecruitingPhase 2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Lymphoplasmacytic Lymphoma, Waldenstrom Macroglobulinemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Paul Ridker, MD, MPH principal investigator
Brigham and Women's Hospital
470 sites in 3 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Methotrexate in people with Cardiovascular Disease, run by Brigham and Women's Hospital at 470 sites in 3 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 Jul 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 470 sites in United States, Canada, Puerto Rico. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 24 Jul 2020). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Subjects With Major Adverse Cardiovascular Events (time frame: From randomization to trial end (April 2, 2018) up to a maximum of 5 years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01594333, which also lists 11 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Jul 2020.